Gilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study fail

Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall Street analysts had projected. Gilead’s shares {$GILD} were up 3% in after ...